VanEck Pharmaceutical ETF (PPH)

Delayed Data
As of 3:59pm ET
 +0.40 / +0.53%
Today’s Change
Today|||52-Week Range

Investment Objective

The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS  US Listed Pharmaceutical 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.


1 month-1.82% 3 years+12.07%
3 months-1.58% 5 years+8.28%
1 year+1.78% Since inception+9.44%
Data through 08/06/2022

Quote Details

Previous close$75.48
Open day’s range75.53 – 76.25
Net asset value (NAV)75.50 (08/05/2022)
Daily volume7,983
Average volume (3 months)181,866
Data as of 3:59pm ET, 08/08/2022

Peer Comparisonvs. Health ETFs

Performance 5-yr return+8.28%+7.33%
Expense Gross exp ratio0.35%1.01%
Risk 5 year sharpe ratio0.480.48
Net assets$571.9M$2.0B
Average market cap$72.4B$43.6B
Average P/E19.622.0
Dividend / Share--0.27%


VHT Vanguard Health Care Index Fund ETF Shar...
FHLC Fidelity MSCI Health Care Index ETF
IEHS iShares Evolved U.S. Healthcare Staples ...


Top 5 Sectors
Portfolio weighting
Business service --
Consumer goods --
Consumer service --
Energy --
Financial service --
Top 10 Holdings
Portfolio weighting
LLY Eli Lilly and Co5.37%
AZN AstraZeneca5.23%
NVO Novo Nordisk5.11%
MRK Merck5.10%
JNJ Johnson & Johnson5.03%
NVS Novartis5.02%
MCK Mckesson Corp4.98%
TAK Takeda Pharmaceutical4.95%
BMY Bristol-Myers Squibb4.95%
ABBV AbbVie4.91%